Searched for
DR REDDYS LABORATORIES
Parag Parikh Flexi Cap Fund raises stake in ITC, HDFC Bank and 14 other stocks in MayParag Parikh Flexi Cap Fund, India’s largest active flexi-cap scheme by AUM, raised exposure to ITC, HDFC Bank and 14 other stocks in May, ...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- SBI Chairman, Apple India MD among 29 members appointed to Board of TradeThe government has appointed 29 non-official members to the Board of Trade. This includes prominent figures like SBI Chairman CS Setty and ...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- India's Shanghai envoy, Chinese official discuss plans to boost culture, tourism tiesIndia's Consul General in Shanghai, Pratik Mathur, met with a Chinese cultural official to boost cultural exchanges and tourism. This aims ...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- These 7 stocks reported declining EPS for 4 straight quartersSeven Nifty 500 stocks, including Dr. Reddy's, GAIL and Torrent Power, have reported sequential declines in quarterly EPS for four straight...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Stocks in news: ITC, Nykaa, Lenskart, Ola Electric, IndusInd BankMarkets saw a volatile session with Nifty trading below the 23,800-24,000 resistance zone, though select heavyweight buying limited downsid...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...
- Rising bond yields, oil prices keeping markets on edge; selective bets still emerging: Pankaj PandeyGlobal markets are under pressure due to rising bond yields and geopolitical tensions. Higher crude oil prices are a key concern, potential...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Reddy Pharma loses 'name' in Delhi HC rulingThe Delhi High Court has ruled against Reddy Pharmaceuticals. The court upheld a decision to remove 'Reddy' from the company's name. Reddy ...
- Stocks in news: Vodafone Idea, Indian Oil, Tata Steel, Dr Reddy's, PFCMarkets closed lower amid geopolitical tensions, rupee weakness, and rising inflation. Upcoming week will be sensitive to US-Iran conflict ...
- Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in CanadaDr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business press...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition spaceDr Reddy's teams up with Nestle Health Science to introduce Celevida GLP+, a specialized supplement crafted for those navigating the challe...
Load More
